Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer Read More »
A phase 2 expansion study of ARV-766, a PROTAC® androgen receptor degrader, in metastatic castration-resistant prostate cancer – Poster Presentation Read More »
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – PLS Read More »
Outcomes in men with metastatic castration-resistant prostate cancer and tumors with certain androgen receptor (AR) mutations Read More »
Real world outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations Read More »
In Vitro Evaluation Of PROTAC® Degrader ARV-110 (Bavdegalutamide) For Cytochrome P450- And Transporter-Mediated Drug-Drug Interaction Read More »
Phase 1b study of Bavdegalutamide, an androgen receptor PROTAC® degrader, combined with abiraterone in patients with metastatic prostate cancer Read More »
Phase 1/2 Study of ARV-110, an Androgen Receptor PROTAC® Degrader, in Metastatic Castration-Resistant Prostate Cancer Read More »
